Introduction:
In recent years, biosimilars have gained significant traction in the pharmaceutical industry, offering more affordable alternatives to expensive biologic drugs. India, known for its thriving pharmaceutical sector, has been at the forefront of biosimilar production and adoption. With a growing demand for cost-effective treatment options, the country has witnessed a surge in biosimilar switching patterns. In 2026, the top 10 biosimilars switching patterns in India are shaping the landscape of the pharmaceutical market.
Top 10 Biosimilars Switching Patterns in India 2026:
1. Adalimumab (Humira) by Biocon: Biocon’s biosimilar of Adalimumab, a popular drug for autoimmune diseases, has captured a significant market share in India. With its high efficacy and competitive pricing, Biocon’s Adalimumab has become a preferred choice for patients and healthcare providers.
2. Trastuzumab (Herceptin) by Mylan: Mylan’s biosimilar of Trastuzumab has emerged as a top contender in the Indian market for breast cancer treatment. The company’s product offers comparable efficacy to the original drug at a lower cost, making it a preferred option for patients seeking affordable treatment.
3. Rituximab by Dr. Reddy’s Laboratories: Dr. Reddy’s biosimilar of Rituximab has gained popularity among Indian patients with blood cancers and autoimmune disorders. The company’s product has shown promising results in clinical trials, solidifying its position as a leading biosimilar in the market.
4. Etanercept (Enbrel) by Lupin: Lupin’s biosimilar of Etanercept has witnessed a steady increase in demand in India due to its effectiveness in treating rheumatoid arthritis and other autoimmune conditions. The company’s product has garnered positive reviews from patients and healthcare professionals alike.
5. Infliximab (Remicade) by Cipla: Cipla’s biosimilar of Infliximab has made significant strides in the Indian market, offering a cost-effective alternative for patients with inflammatory bowel disease and rheumatoid arthritis. The company’s product has gained a strong foothold in the biosimilar segment.
6. Bevacizumab (Avastin) by Cadila Healthcare: Cadila Healthcare’s biosimilar of Bevacizumab has become a preferred choice for cancer patients in India, thanks to its affordability and efficacy. The company’s product has been widely embraced by oncologists for its positive outcomes in cancer treatment.
7. Pegfilgrastim (Neulasta) by Sun Pharma: Sun Pharma’s biosimilar of Pegfilgrastim has seen a surge in demand among Indian patients undergoing chemotherapy. The company’s product has demonstrated comparable efficacy to the original drug, making it a popular choice for cancer treatment.
8. Epoetin Alfa (Epogen) by Glenmark Pharmaceuticals: Glenmark Pharmaceuticals’ biosimilar of Epoetin Alfa has gained traction in the Indian market for its effectiveness in treating anemia in patients with chronic kidney disease. The company’s product has been well-received by nephrologists for its quality and affordability.
9. Filgrastim (Neupogen) by Intas Pharmaceuticals: Intas Pharmaceuticals’ biosimilar of Filgrastim has become a top choice for cancer patients in India requiring chemotherapy. The company’s product has shown comparable efficacy to the original drug, making it a preferred option for oncologists.
10. Insulin Glargine (Lantus) by Aurobindo Pharma: Aurobindo Pharma’s biosimilar of Insulin Glargine has gained popularity among diabetic patients in India for its affordability and quality. The company’s product has emerged as a leading biosimilar in the insulin segment, offering a cost-effective treatment option for patients.
Insights:
The biosimilar market in India is poised for continued growth in the coming years, driven by increasing demand for affordable treatment options and favorable government policies promoting biosimilar adoption. With a strong focus on research and development, Indian pharmaceutical companies are expected to launch more innovative biosimilars, further expanding the market. By leveraging their manufacturing capabilities and expertise, Indian companies can continue to capture a larger share of the global biosimilar market, positioning the country as a key player in the pharmaceutical industry. As biosimilars become increasingly mainstream in India, patients are likely to benefit from improved access to essential treatments at lower costs, ultimately improving healthcare outcomes nationwide.
Related Analysis: View Previous Industry Report
